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POSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immu-
nosuppression. I Previous reports of patients immunosup-
pressed with cyclosporine (eyA) revealed a 1.7% inci-
dence of PTLD in solid-organ transplant recipients and a 
strong association with the Epstein-Barr virus «EBV). ~ 
The use of FK 506 in clinical trials has resulted in im-
proved patient and graft survival. as well as a reduction in 
the prevalence of infectious complications and as a result 
infection-related mortality . Kf·~ PTLD has also been seen 
among the complications observed in patients treated with 
FK 506. having a reported incidence of 0.7% to 1.5%. ~Kff 
This report descnbes the clinical and pathologic features of 
PTLD arising In the solid-organ transplant recipients 
treated primarily with FK 506. 
MATERIALS AND METHODS 
Case Material 
Between March I. 1989 and June I. 1991. a 10lal of 936 pallenls 
rectived FK 506 as Ihe "nmary immunosuppressive Iherapy for 
their fi~t organ Ir.lnsplant al the University of Pillsburgh. This 
group comprised ~RR liver recipienls. ~1T kidney reCipients. 67 
hean reCipients. 41 reCIpients of liver plus other organs. I heart! 
lung recIpient. and 2 lung reCipients. In addition. 53 pallents are 
included who received FK S06 for diverse transplant indications 
including pancreallc Islets. small intesllne. bone marrow. and 
kidnev plus one or more organs. as well as various putallve 
autoimmune dl~easeyK Within IhlS populaltlln. loll pedlatnc pa· 
ffC:nt~ lAo::re tran~lDflantc:oK Indudin!! IIln hvc:r reclpu:n". In kiunev 
reClplent'i. anu f~ ho::an reCIpients. 
The pnmary Immunosuppression used In each case consIsted of 
FK ~MS combined lAllh low-dose predmsone as descnbed prevI-
ously. Supplemental ImmunosuppreSSion l'or episodes of acute 
cellular rejection Included pulse doses of methylpredmsolone. 
.1Odior prednisone rec\'cles. wllh OKTJ reserved for cases of 
,terold·reslstant reJection. 
PathOlogiC Studies 
rhe palholOl,!IC dla!!no~1y uf a pO,UrJn,plant I\,mphllprohfer.lll\·e 
ul~oruer I PTl.DI Inciulled Ihe enllre ,pectrum 01 alvplcal I,m· 
phoprohferallon ansln!! In a IrJnsplant populallon. Buth the 
hl~tolll!!fC appearance anolhe phenOl\ pIC anal\'", llf dllnal ,laIU, 
"as a"e\\ell in each ':J'':. All a\allable ,uqllcal and aulUp", 
,!'Cclmen, J' \\.0:11 J' .I\allable EBV ,c:rolu!!lC dal;1 from Ihe,e 
pallenlS \\.o::re reVlelAeo, 
RESULTS 
Patient Population ana Tumor InCidence 
During the study pcnQ(i. a total of 15 PTLD, were tdent!-
tied. Seven OCCUlTed In males. and II OCCUlTed In fc:males 
(M:F ratio. 0.8711). The age of the recipients at the time of 
transplantation ranged from 4 months to 65 years. with a 
median age of 19 years. Six patients were under 18 years of 
age. One patient was over 55 years of age. The time 
between the date of the organ transplant and the date of 
tumor identification in this group of IS organ graft recipi-
ents having a PTLD ranged between 30 and 351 days. with 
a median of 70 days. The mean follow-up time was 10 
months. 
These 15 cases represent 1.6% of the total study popu-
lation. The distribution of cases relative to the organ 
transplanted revealed a total of 13 cases in liver graft 
recipients and 2 in kidney graft recipients. resulting in a 
..:orresponding prevalence of 2.3% for liver transplantation 
and 0.9% for kidney transplantation. Interestingly. no case 
of PTLD occurred in a patient in whom the liver was 
transplanted in association with another organ. or in any 
recipients of a heart. heart/lung. isolated lung. or patient 
receiving FK 506 for the indications included in the "mis-
cellaneous" category. When the pediatric population was 
analyzed as a separate group. a PTLD incidence of 4.7% 
for liver reCIpients and 6.2% for kidney recipients was 
noted. 
Clinical Presentation and location of the PTlD 
Symptoms of fever. malaise. and weight loss were present 
in most pallents and were nonspecific. The predominant 
,lIe of invulvement for each PTLD dictated the manner 10 
whIch the disease presented. i~Dmphadenopathy was 
noted in eight patients 153%). five 128%) of which were 
located in the head and neck regIon. and usually assocIated 
with other symptoms. However. one patient presented 
with an asymptomatic mass in the left groin. Eight patients 
1RP~F had involvement of their gastrointestinal tract char-
acterIzed predominantly by the presence of an ulcerated 
bleeding tumor. Isolated stomach. small bowel. and colon 
From the Oepanment of Surgery. Pathology ana InfectiOUS 
Disease. UniversItY Health Center of Pittsburgh. UnlVersrty of 
Pittsburgn. ana the Velerans Administration Medical Center. Pins· 
burgh. Pennsylvania. 
SUPPQrtea by researCh grants from the Veterans Admlnlslrallon 
ana PrOJect Grant NO. OK 29961 from the NatlOn8l InSlnUles 01 
Health. Bethesaa. Maryland. 
Address repnm reQUeslS to Jorge Reyes. MD. UnIVerSity of 
PittSburgh. 3601 Fifth Avenue. 5W Falk Clinic. Pittsburgh. PA 
15213. 
, 1991 by Apt)leton & Lange 
0041-1345. 91.$3.001 .. 0 
3044 qD~"tfon Proce«JIfI(}s, Vol 23. No 6 (Decemcer,. 1991: pp 3044=3046 
LYMPHOPROUFERATIVE DISORDERS 
involvement were seen in three patients respectively: five 
patients (63%) presented with disease involving more than 
one of these sites. One pediatric patient presented with 
small bowel perforation. Six patients (40%) presented with 
nonspecific signs and symptoms which included abdominal 
pain. vomiting. diarrhea. or gastrointestinal bleeding. 
Three patients (20%) required colectomies: two for control 
of bleeding and one for tumor management. Four patients 
126%1. ail liver graft rectpients. presented with disease in 
their graft. Three of these four patients developed graft 
failure. as a result of diffuse graft replacement with tumor 
and died having first been retransplanted. One liver recip-
ient developed a tumor mass in the left hepauc lobe which 
was treated with a left hepatic lobectomy. Three patients 
(20%) had their PTLD occur in the thoracic cavity: the 
epicardium and lung were involved in one patient and the 
lung in two others. The patient with both epicardial and 
lung disease died from disseminated PTLD. Two patients 
(13%) had involvement of their central nervous system 
(eNS). which was idenufied only at autopsy. Two patients 
113%) developed a hemolytic syndrome ofuncenain etiol-
ogy; each of these (Wo cases had a splenectomy In an 
Jttempt to control the hemolysis. Moreover. each went on 
to develop graft failure and died_ 
Pathological Features of PTlD Under 
FK 506 Immunosuppression 
The PTLD seen in this series had a similar range of 
histopathology (monomorphic/polymorphic). as described 
previously among patients treated with CyA. A polymor· 
phic PTLD. in which a wide range of identifiable B 
lymphocyte fonns could be recognized. was seen in nine 
patients. Seven of these were polyclonal and two were 
monoclonal an ongm. A monomorphic PTLD haVing a 
umform proliferation of cells at one stage of differentiation 
was seen In SIX. cases: one of these was monoclonal and 
nve were polyclonai. 
SerologiC eVidence of EBV infection was found in all of 
the 15 patients; 12 were pnmary and 3 nonpnmary infec-
(ions. All of the pediatric patients presented evidence of 
pnmary infections. Eight of the patients had contempora-
neous Infections at the time of tumor diagnosis. Five 
patients had cytomegalovirus infections. 5 patients had 
severe bactenal infections. and I patient had an aspergillus 
lung abscess. 
Treatment 
Treatment of PTLD included reduction of immunosup-
pression combined with IV acyclOVir 11500 mg/m~ TID in 
children and 10 mg;kg TID in adults) and surgery lelther 
for diagnOSIs or treatment of a symptomatic leSIon). In 
each case. the immunosuppressIon being utilized was 
reduced or stopped entirely while there was eVidence of 
clinical disease. Thineen pauents 186%) had at least one 
SUl'8lcaJ procedure directed at the PTLD. which included a 
SUperfiCial lymph node biopsy 16 patients). resection of a 
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ponion of the gastrointestinal tract (4 patients). splenec-
tomy 12 patients). and retransplantauon n patients,-
Outcome 
Ten of the 15 patients diagnosed with PTLD have sUI"\'i"ed 
with a mean foHow-up time of 10 months. At the time of 
this repon. all surviving pauents have had complete remts-
slon of their disease. Nine of the survIving patients had 
disease localized either to lymph nodes 1 usually one ~lFrmK 
Ie. head/neck. thorax. or abdommall or singie-orgJ./l in-
volvement. One patient had both lymph node and solid-
organ involvement. The histologiC and clonal chara.:tens-
IICS of the tumors present in the sUl"\wors were Similar to 
those present in the five patients who died. AUtO sur. Iving 
patients have retained their grafts. Eight of these patients 
are presently on maintenance immunosuppressIon using 
FK 506. Two pediatric patients have been completely off 
Immunosuppression for 2 and 9 months. respectlvel\'. Two 
of the liver reCipients and the two kidney recipients are on 
a maintenance dose of prednisone of between 2.5 and 12.5 
mg;d. Three pediatric liver recipients and I pediatnc 
kidney recipient developed rejection after resolution llf the 
PTLD. These patients were treated successfull~ with 
resumption of maintenance FK 506 therapy and a single 
prednisone dose. 
All five deaths in this series of PTLD occurred in 
recipients of a liver graft. The median time from transplant 
to death. as a result of PTLD. was 7t days. Patients m this 
group had both lymph node as well as solid-organ involve-
ment. including the hepatic graft in three of the five Ib09r). 
Of the five patients who died. two were identified as having 
residual PTLD at autopsy. Four of the five pauents (80%) 
had concomitant severe bactenal. fungal. or viral infec-
t ions. which were major contnbutors to the death of these 
patients. Three of the five patients 160%) who died had 
received OKT3 sometime dunng their course. Four of 
these patients receIved more than one graft. 
DISCUSSION 
The overall incidence of PTLD for all patients receiving 
FK 506 as primary immunosuppressIon was I.or,.. The 
median time between transplant and tumor diagnOSIs was 
~K4 months. which compares favorablv with the transplant 
population treated with conventional immunosuppressIon. 
Both monoclonal and polyclonal tumors occurred with a 
similar range of histology as seen in PTLDs occumng with 
CyA-based regimensK~·T Differences m the rate of PTLD 
frequency eXist among the vanous organ allograft subpop-
ulations. with liver recipients havmg the highest rate of 
PTLD in patients receiving FK 506. 
A Iymphadenopathic presentation. panicularly that re-
stricted to the head and neck region. or an isolated 
smgle-organ presentation. eIther thoraCIC or abdominal. 
has a good prognosis with reduced immunosuppression. 
IV acyclovir. and supponlve surgery. Disseminated dis-
ease. panlcularty when mvolving the graft. repntiess of 
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therapy. was associated with a poor overall survival. 
AssocIated infections were significant contributors to 
death in these patients. 
In summary. FK 506 does not result in an increased 
incidence. morbidity. or mortality for PTLD. 
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